InterCure H1 Revenue NIS125.733M Down From NIS208.614M YoY, Adjusted EBITDA NIS20.829M Down From NIS29.669M YoY

2024-08-30 16:13

Revenues for the first half of 2024 were affected by damages caused by the terrorist attack on October 7, 2023, and the war in Gaza.
InterCure is entitled to full compensation from the Israeli authorities for all direct and indirect damages caused to its Southern Facility located at Kibbutz Nir Oz. To date, InterCure has already received tens of millions of NIS as partial advance payments from the Israeli authorities.
Announced Expansion of its strategic partnership with Cookies™ to Germany and expects to launch first Cookies products in Germany in the fourth quarter of 2024.
Restoring the Southern Facility continues in accordance with receiving advance payments from the Israeli authorities.
Expects double digit growth throughout the second half of 2024 (compared to first half of 2024) due to expected launches in German and UK markets.